Natixis Advisors LLC Increases Position in CONMED Co. (NYSE:CNMD)

Natixis Advisors LLC lifted its stake in shares of CONMED Co. (NYSE:CNMD - Free Report) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,550 shares of the company's stock after purchasing an additional 11,641 shares during the period. Natixis Advisors LLC owned about 0.40% of CONMED worth $8,387,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Champlain Investment Partners LLC lifted its holdings in CONMED by 6.4% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,367,650 shares of the company's stock valued at $98,361,000 after purchasing an additional 81,970 shares in the last quarter. Geode Capital Management LLC raised its position in shares of CONMED by 1.2% in the third quarter. Geode Capital Management LLC now owns 693,400 shares of the company's stock valued at $49,879,000 after buying an additional 8,274 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of CONMED by 0.7% in the fourth quarter. Principal Financial Group Inc. now owns 625,058 shares of the company's stock valued at $42,780,000 after buying an additional 4,343 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in shares of CONMED by 0.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 501,803 shares of the company's stock worth $36,090,000 after buying an additional 4,032 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in CONMED by 41.4% during the 4th quarter. Fisher Asset Management LLC now owns 417,430 shares of the company's stock valued at $28,569,000 after acquiring an additional 122,140 shares in the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CNMD shares. Wells Fargo & Company reduced their price objective on CONMED from $74.00 to $70.00 and set an "equal weight" rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC lowered their price target on shares of CONMED from $97.00 to $91.00 and set a "buy" rating on the stock in a research report on Thursday, February 6th. JPMorgan Chase & Co. lowered shares of CONMED from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $85.00 to $70.00 in a report on Thursday, February 6th. Finally, Stifel Nicolaus lifted their price target on shares of CONMED from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, CONMED currently has an average rating of "Moderate Buy" and an average target price of $77.20.

CONMED Stock Down 1.8 %

Shares of CNMD stock traded down $1.10 during trading on Tuesday, reaching $59.70. The company's stock had a trading volume of 550,265 shares, compared to its average volume of 440,322. CONMED Co. has a 1-year low of $55.22 and a 1-year high of $81.22. The stock's 50-day moving average price is $64.41 and its 200 day moving average price is $68.35. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 14.08, a P/E/G ratio of 1.83 and a beta of 1.53. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.30 and a quick ratio of 1.06.

CONMED (NYSE:CNMD - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. On average, research analysts anticipate that CONMED Co. will post 4.35 EPS for the current year.

CONMED Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 4th. Shareholders of record on Friday, March 14th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Friday, March 14th. CONMED's dividend payout ratio is currently 18.87%.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.